company-logo

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Therapeutics Dividend Announcement

RAPT Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on RAPT Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

RAPT Therapeutics Dividend History

RAPT Therapeutics Dividend Yield

RAPT Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing RAPT Therapeutics stock? Use our calculator to estimate your expected dividend yield:

RAPT Therapeutics Financial Ratios

P/E ratio-0.56
PEG ratio0.01
P/B ratio0.62
ROE-86.04%
Payout ratio0.00%
Current ratio8.14
Quick ratio8.14
Cash Ratio2.51

RAPT Therapeutics Dividend FAQ

Does RAPT Therapeutics stock pay dividends?
RAPT Therapeutics does not currently pay dividends to its shareholders.
Has RAPT Therapeutics ever paid a dividend?
No, RAPT Therapeutics has no a history of paying dividends to its shareholders. RAPT Therapeutics is not known for its dividend payments.
Why doesn't RAPT Therapeutics pay dividends?
There are several potential reasons why RAPT Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will RAPT Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While RAPT Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is RAPT Therapeutics a dividend aristocrat?
RAPT Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is RAPT Therapeutics a dividend king?
RAPT Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is RAPT Therapeutics a dividend stock?
No, RAPT Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy RAPT Therapeutics stocks?
To buy RAPT Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy RAPT Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.